Fresenius SE & Co (FSNUY) AI Stock Analysis

• Market Cap: $31.52B
• Dividend Yield: 2%
• Average Volume (3M): 5.22K
• Price to Earnings (P/E): 25.0
• Beta (1Y): 0.18
• Revenue Growth: 2.59%
• EPS Growth: N/A
• Country: US
• Employees: 175,202
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.24
• Shares Outstanding: 2,252,949,200
• 10 Day Avg. Volume: 3,154
• 30 Day Avg. Volume: 5,216
• PEG Ratio: -0.89
• Price to Book (P/B): 3.90
• Price to Sales (P/S): 3.49
• P/FCF Ratio: 49.97
• Enterprise Value/Market Cap: 1.44
• Enterprise Value/Revenue: 2.04
• Enterprise Value/Gross Profit: 8.02
• Enterprise Value/Ebitda: 13.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.98
• Revenue Forecast (FY): $26.07B

• Rating: 67 Neutral
• Price Target: $15.00 ▲(6.84% Upside)

Fresenius SE & Co's overall stock score is driven by strong earnings call performance and stable financials, despite valuation concerns and cash flow challenges. The company's strategic focus and operational execution are positive indicators for future growth.

Fresenius SE & Co Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA is a global healthcare group based in Germany, operating primarily in the sectors of healthcare, particularly dialysis, hospital management, and pharmaceuticals. The company is structured into several business segments, including Fresenius Medical Care, which focuses on dialysis products and services; Fresenius Helios, which operates private hospitals; and Fresenius Kabi, which specializes in intravenous therapies and clinical nutrition. The company’s core offerings include dialysis machines, consumables, hospital management services, and a wide range of generic drugs and medical devices.

How the Company Makes Money

Fresenius generates revenue through multiple key streams. The largest segment, Fresenius Medical Care, earns revenue by providing dialysis treatments, equipment, and related services to patients with chronic kidney failure around the world. This segment benefits from a large patient base and long-term contracts with healthcare providers. Fresenius Helios contributes significantly to revenue through the operation of private hospitals in Germany, where it receives payments for medical services provided to patients. Fresenius Kabi adds to the revenue through the sale of generic pharmaceuticals, intravenous solutions, and medical devices, capitalizing on the growing demand for healthcare products. Additionally, strategic partnerships and acquisitions enhance its market position and revenue potential, allowing Fresenius to expand its service offerings and geographic reach.

Fresenius SE & Co Financial Statement Overview

Summary

Fresenius SE & Co demonstrates stable financial performance with moderate growth and profitability. The balance sheet shows improved leverage and a strong equity position, but cash flow challenges persist with negative free cash flow growth.

Income Statement

Fresenius SE & Co shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a slight improvement in revenue growth at 0.547%, recovering from a negative trend in the previous year. Gross profit margin remains stable at around 24%, but the net profit margin is relatively low at 1.91%, indicating potential cost pressures. EBIT and EBITDA margins are moderate, suggesting operational efficiency but room for improvement in profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.70, which is an improvement from previous years, indicating better leverage management. Return on equity is modest at 2.20%, suggesting limited returns on shareholder investments. The equity ratio stands at approximately 44.23%, showing a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals challenges with a negative free cash flow growth rate of -25.88% in the TTM period, highlighting potential cash generation issues. The operating cash flow to net income ratio is 0.31, indicating adequate cash flow generation relative to net income. The free cash flow to net income ratio is 0.64, suggesting that a significant portion of net income is converted into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.23B	21.83B	22.30B	40.84B	37.52B	36.28B
Gross Profit	5.65B	5.38B	5.06B	10.72B	10.31B	10.32B
EBITDA	3.48B	3.14B	2.73B	3.09B	6.84B	7.19B
Net Income	1.13B	471.00M	-594.00M	1.37B	1.82B	1.71B
Balance Sheet
Total Assets	41.32B	43.55B	45.28B	76.42B	71.96B	66.65B
Cash, Cash Equivalents and Short-Term Investments	1.39B	2.05B	2.56B	2.35B	2.75B	2.00B
Total Debt	12.85B	13.58B	15.83B	27.76B	27.16B	25.91B
Total Liabilities	22.38B	23.26B	25.63B	44.20B	42.67B	40.62B
Stockholders Equity	18.28B	19.54B	19.00B	20.41B	19.00B	16.95B
Cash Flow
Free Cash Flow	1.24B	1.52B	3.32B	2.28B	3.03B	4.14B
Operating Cash Flow	2.21B	2.45B	4.46B	4.20B	5.08B	6.55B
Investing Cash Flow	-559.00M	-510.00M	-3.19B	-2.61B	-2.82B	-3.01B
Financing Cash Flow	-1.51B	-2.18B	-1.38B	-1.60B	-1.45B	-3.12B

Fresenius SE & Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 14.04 is below the 20-day moving average (MA) of 14.18, above the 50-day MA of 13.96, and above the 200-day MA of 12.20, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 52.17 is Neutral, neither overbought nor oversold. The STOCH value of 63.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.

Fresenius SE & Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UHS	78 Outperform	$14.32B	10.69	19.97%	0.36%	10.21%	39.58%
HCA	77 Outperform	$107.86B	18.27	―	0.63%	6.82%	15.82%
THC	73 Outperform	$16.95B	13.23	34.51%	―	-0.56%	-53.50%
FSNUY	67 Neutral	$31.52B	25.03	7.22%	2.00%	2.59%	―
FMS	65 Neutral	$13.90B	17.42	5.31%	3.37%	4.09%	13.17%
DVA	58 Neutral	$8.58B	12.52	―	―	5.14%	4.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Fresenius SE & Co Corporate Events

Fresenius SE Reports Strong Q3 2025 Performance

Fresenius SE & Co. KGaA is a global healthcare company based in Germany, specializing in biopharmaceuticals, clinical nutrition, medical technology, and hospital management, with significant operations in Germany and Spain.

Fresenius SE Earnings Call: Growth Amid Challenges

Fresenius SE’s recent earnings call presented a mixed sentiment, balancing strong growth in core EPS and revenue guidance upgrades with challenges in specific markets. The positive performance in the Kabi and Biopharma divisions was tempered by concerns over the Keto tender impact in China, Helios Germany’s headwinds, and uncertainties related to FX and tariffs.

Fresenius SE Reports Strong Q2 2025 Earnings

Fresenius SE & Co. KGaA is a global healthcare company based in Germany, operating through its subsidiaries Fresenius Kabi and Fresenius Helios, and is known for its extensive hospital network and diverse pharmaceutical offerings.